Antidepressants, including serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors, are widely used in the United States despite a number of unknowns related to their clinical performance. One of the biggest unknowns stems from the dearth of evidence on the efficacy of the drugs over the long term, as most studies have followed up with participants for only 8 to 12 weeks. Researchers also do not know much about how antidepressants affect mental and physical quality of life over time.

The US Preventive Task Force (USPSTF) has updated its 2016 recommendation on the use of aspirin to protect against cardiovascular disease (CVD) and colorectal cancer (CRC).

More than 50% of people all over the world experienced a headache disorder in the past year, according to new research published in the Journal of Headache and Pain. The disorders—which include migraines, tension headaches, cluster headaches, and headaches related to things like exercise or sinusitis—affect 52% of people, the study found. Each day, an estimated 15.8% of the world’s population has a headaches, the researchers said.

FDA issued a draft guidance document for developing plans to enroll more participants in clinical trials from underrepresented racial and ethnic populations. The draft guidance advises sponsors of medical products to develop and submit a race and ethnicity diversity plan based on a framework outlined in the guidance to the agency early in clinical development.

The American Academy of Sleep Medicine has initiated an investigation into the safety of melatonin, which is increasingly used as a solution for chronic insomnia.